Edition:
United States

Auris Medical Holding AG (EARS.OQ)

EARS.OQ on NASDAQ Stock Exchange Capital Market

0.30USD
13 Jul 2018
Change (% chg)

$-0.26 (-47.14%)
Prev Close
$0.56
Open
$0.33
Day's High
$0.33
Day's Low
$0.28
Volume
1,761,331
Avg. Vol
106,288
52-wk High
$9.50
52-wk Low
$0.28

Chart for

About

Auris Medical Holding AG is a Switzerland-based biotechnology company engaged in developing pharmaceutical products for the treatment of inner ear disorders and mental health supportive care. The Company focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsycho... (more)
No analyst recommendations are available for .

Overall

Beta: 0.41
Market Cap(Mil.): $1.81
Shares Outstanding(Mil.): 6.12
Dividend: --
Yield (%): --

Financials

  EARS.OQ Industry Sector
P/E (TTM): -- 214.97 33.20
EPS (TTM): -3.85 -- --
ROI: -109.29 -3.79 13.23
ROE: -388.47 -5.32 15.28

BRIEF-Auris Medical Provides Q1 Loss Per Share CHF 0.30

* AURIS MEDICAL PROVIDES BUSINESS AND STRATEGY UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 15 2018

BRIEF-Auris Medical Receives Positive Scientific Advice From EMA On Development Plan And Regulatory Pathway For AM-111

* AURIS MEDICAL RECEIVES POSITIVE SCIENTIFIC ADVICE FROM EMA ON DEVELOPMENT PLAN AND REGULATORY PATHWAY FOR AM-111

May 07 2018

BRIEF-Auris Medical Announces Early Repayment Of Part Of Its Loan Facility

* AURIS MEDICAL ANNOUNCES EARLY REPAYMENT OF PART OF ITS LOAN FACILITY

Apr 09 2018

BRIEF-Thomas Meyer Reports 12.6 Pct Stake In Auris Medical As Of March 29

* THOMAS MEYER REPORTS 12.6 PCT STAKE IN AURIS MEDICAL HOLDING AG AS OF MARCH 29, 2018 - SEC FILING‍​ Source text: (https://bit.ly/2uJaqwA) Further company coverage:

Apr 03 2018

BRIEF-Auris Regains Compliance With Nasdaq's Minimum Bid Price Requirement

* AURIS REGAINS COMPLIANCE WITH NASDAQ'S MINIMUM BID PRICE REQUIREMENT Source text for Eikon: Further company coverage:

Mar 29 2018

BRIEF-Auris Medical Q4 Loss Per Share CHF 0.10

* AURIS MEDICAL PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 22 2018

BRIEF-Auris Medical Holding AG - Shareholders Approved Merger Between Co And Auris Medical Newco - SEC Filing

* AURIS MEDICAL HOLDING AG - ON MARCH 12, AT THE GENERAL MEETING, SHAREHOLDERS APPROVED MERGER BETWEEN CO AND AURIS MEDICAL NEWCO - SEC FILING

Mar 13 2018

BRIEF-Auris Medical Provides Business Update

* AURIS MEDICAL HOLDING AG - PRELIMINARY TOP-LINE DATA FROM TACTT3 TRIAL INDICATE THAT STUDY DID NOT MEET ITS PRIMARY EFFICACY ENDPOINT

Mar 13 2018

BRIEF-Auris Medical Holding AG Files For Resale Of Up To 7.5 Mln Common Shares Issuable Upon Exercise Of Certain Outstanding Warrants

* AURIS MEDICAL HOLDING AG FILES FOR RESALE OF UP TO 7.5 MILLION COMMON SHARES ISSUABLE UPON EXERCISE OF CERTAIN OUTSTANDING WARRANTS - SEC FILING Source text: [http://bit.ly/2BPfTod] Further company coverage:

Feb 09 2018

BRIEF-Auris Medical Reports New Data Highlighting Superior Bioavailability Of AM-125

* AURIS MEDICAL REPORTS NEW DATA HIGHLIGHTING SUPERIOR BIOAVAILABILITY OF AM-125 COMPARED TO ORAL BETAHISTINE

Feb 07 2018

Earnings vs. Estimates